Elsayed M, Loya M, Galt J, Schuster DM, Bercu ZL, Newsome J, Brandon D, Benenati S, Behbahani K, Duszak R, Sethi I, Kokabi N. Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond. World J Gastrointest Oncol 2021; 13(5): 440-452 [PMID: 34040704 DOI: 10.4251/wjgo.v13.i5.440]
Corresponding Author of This Article
Keywan Behbahani, BSc, Academic Research, Division of Interventional Radiology and Image-Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, 201 Dowman Dr, Atlanta, GA 30322, United States. kbehbah@emory.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Elsayed M, Loya M, Galt J, Schuster DM, Bercu ZL, Newsome J, Brandon D, Benenati S, Behbahani K, Duszak R, Sethi I, Kokabi N. Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond. World J Gastrointest Oncol 2021; 13(5): 440-452 [PMID: 34040704 DOI: 10.4251/wjgo.v13.i5.440]
World J Gastrointest Oncol. May 15, 2021; 13(5): 440-452 Published online May 15, 2021. doi: 10.4251/wjgo.v13.i5.440
Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond
Mohammad Elsayed, Mohammad Loya, James Galt, David M Schuster, Zachary L Bercu, Janice Newsome, David Brandon, Sonia Benenati, Keywan Behbahani, Richard Duszak, Ila Sethi, Nima Kokabi
Mohammad Elsayed, Mohammad Loya, Zachary L Bercu, Janice Newsome, Sonia Benenati, Keywan Behbahani, Richard Duszak, Nima Kokabi, Division of Interventional Radiology and Image-Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, United States
James Galt, David M Schuster, David Brandon, Ila Sethi, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, United States
Author contributions: Elsayed M collected the data, performed the analysis, and wrote the paper; Loya M, Newsome J and Duszak R contributed to critical analysis and review of the manuscript; Galt J, Bercu ZL, Brandon D and Sethi I collected and contributed the data and analysis tools; Bercu ZL contributed to the data and the critical review of the manuscript; Benenati S collected and contributed the data; Behbahani K wrote the paper and provided critical review of the manuscript; Kokabi N conceived and designed the analysis and provided critical review of the manuscript.
Institutional review board statement: This series has been approved by the local Institutional Review Board, and the need for written informed consent was waived.
Conflict-of-interest statement: No authors received specific funding for the development of this manuscript. Kokabi N conducts Y-90 radioembolization research partially funded by Sirtex Medical Ltd; Duszak R receives research support from the Harvey L. Neiman Health Policy Institute.
Data sharing statement: No additional data is available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Keywan Behbahani, BSc, Academic Research, Division of Interventional Radiology and Image-Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, 201 Dowman Dr, Atlanta, GA 30322, United States. kbehbah@emory.edu
Received: December 8, 2020 Peer-review started: December 8, 2020 First decision: March 8, 2021 Revised: March 21, 2021 Accepted: April 23, 2021 Article in press: April 23, 2021 Published online: May 15, 2021 Processing time: 149 Days and 11.7 Hours
ARTICLE HIGHLIGHTS
Research background
Yttrium-90 (Y-90) radioembolization (RE) is an intra-arterial targeted liver therapy for patients with hepatic malignancies. Recent publications demonstrate that Y-90 RE can be performed as a single combined procedure, rather than a staged procedures performed over multiple days.
Research motivation
Given the coronavirus disease 2019 (COVID-19) pandemic, there has been an increased need to mitigate infection risk and logistical challenges. By reducing the number of in-person visits, same day Y-90 RE provides an opportunity to improve patient care for oncology patients during the COVID-19 and beyond. However, existing literature describing same day Y-90 RE predominantly report the use of planar scintigraphy without single photon emission computed tomography/computed tomography (SPECT/CT), which may limit the ability to optimize therapy for patients with more advanced malignancies. This retrospective analysis describes the use of pre- and post-treatment SPECT/CT with personalized dosimetry during the COVID-19 pandemic.
Research objectives
Describe the use of same day Y-90 RE with routine SPECT/CT.
Research methods
A same day procedure was developed, consisting of angiography, imaging, and Y-90 resin particle delivery. Routine SPECT/CT after Tc-99m MAA administration was performed for assessment of arterial supply, personalized dosimetry, and extrahepatic activity. Post-treatment Y-90 bremsstrahlung SPECT/CT was performed for confirmation of particle delivery, by utilization of energy windowing to limit signal from previously administered Tc-99m MAA particles.
Research results
A total of 14 patients underwent same day Y-90 RE with SPECT/CT. Mean lung shunt fraction was 6.13% (range 3.5%-13.1%). Y-90 RE was performed for a single lesion in 7 patients, while the remaining 7 patients had treatment of multifocal lesions. All patients tolerated the procedure well and were discharged the same day.
Research conclusions
Same day Y-90 RE with resin-based microspheres is feasible, and provides an opportunity to mitigate infection risk and logistical challenges associated with the COVID-19 pandemic. Consideration of routine SPECT/CT is recommended, especially among patients with complex malignancies, for the potential to improve outcomes and eligibility of patients to undergo same day Y-90 RE.
Research perspectives
Further studies of long-term patient outcomes and cost-benefit analyses would be useful to validate the utility of same day Y-90 with SPECT/CT.
